Valiant Laboratories Ltd 09 Feb 2024 12:00 AM
Valiant Laboratories reports standalone net loss of Rs 3.50 crore in the December 2023 quarter,
Net loss of Valiant Laboratories reported to Rs 3.50 crore in the quarter ended December 2023 as against net profit of Rs 7.65 crore during the previous quarter ended December 2022. Sales declined 42.74% to Rs 40.52 crore in the quarter ended December 2023 as against Rs 70.77 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales40.5270.77 -43 OPM %-15.6014.03 - PBDT-4.5610.67 PL PBT-5.0510.27 PL NP-3.507.65 PL Powered by Capital Market - Live News
Valiant Laboratories Ltd 02 Feb 2024 12:00 AM
Valiant Laboratories to convene board meeting,
Valiant Laboratories will hold a meeting of the Board of Directors of the Company on 9 February 2024.Powered by Capital Market - Live News
Valiant Laboratories Ltd 07 Nov 2023 12:00 AM
Valiant Laboratories standalone net profit declines 90.88% in the September 2023 quarter,
Net profit of Valiant Laboratories declined 90.88% to Rs 0.79 crore in the quarter ended September 2023 as against Rs 8.66 crore during the previous quarter ended September 2022. Sales declined 32.30% to Rs 59.55 crore in the quarter ended September 2023 as against Rs 87.96 crore during the previous quarter ended September 2022. ParticularsQuarter Ended�Sep. 2023Sep. 2022% Var. Sales59.5587.96 -32 OPM %-2.3312.15 - PBDT1.5511.99 -87 PBT1.0611.62 -91 NP0.798.66 -91 Powered by Capital Market - Live News
Valiant Laboratories Ltd 02 Nov 2023 12:00 AM
Valiant Laboratories to declare Quarterly Result,
Valiant Laboratories will hold a meeting of the Board of Directors of the Company on 6 November 2023.Powered by Capital Market - Live News
Valiant Laboratories Ltd 25 Oct 2023 12:00 AM
Valiant Laboratories to invest Rs 165.04 cr in WoS - Valiant Advanced Sciences,
Valiant Laboratories has agreed to acquire 16030 equity shares of Rs. 10 each and 5130 optionally convertible preference shares of Rs. 10/- each aggregating to Rs. 165,04,80,000 by way of subscribing to the rights issue of Valiant Advanced Sciences (VASPL), wholly owned subsidiary of the company. Powered by Capital Market - Live News
Subscribe for our
newsletter
Open Account Now